| Document |
Document Title |
|
WO/2015/080182A1 |
A compound that is represented by general formula (1), the compound being useful as a light-emitting material. X represents SO2, P(=O)(Ar1), Ge(Ar2)(Ar3), Si(Ar4)(Ar5), or Sn(Ar6)(Ar7), and Ar1-Ar7 each independently represents a substit...
|
|
WO/2015/051766A1 |
The present invention relates to amide substituted indazoles and benzotriazoles which are inhibitors of the enzyme poly (ADP-ribose) polymerase (PARP), previously known as poly (ADP-ribose) synthase and poly (ADP-ribosyl) transferase. Th...
|
|
WO/2015/036560A1 |
The invention relates to novel heterocyclic substituted 6-(trifluoromethyl)pyrimidine- 4(3H)-one derivatives, to a method for the production thereof, to the use thereof either alone or in combination for the treatment and/or prevention o...
|
|
WO/2015/028989A1 |
The invention relates to novel heterocyclic compounds of the Formula I. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more compounds of...
|
|
WO/2015/031295A1 |
There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, vi...
|
|
WO/2015/030057A1 |
A morpholine derivative represented by general formula [1A] or a salt thereof. In the formula, the ring A represents a ring represented by general formula [I] or the like; * represents a binding position; Z2 represents CH or the like; Z1...
|
|
WO/2015/008872A1 |
This invention relates to a cyanotriazole compound represented by the formula (1):, wherein each symbols are defined in the specification, or a salt thereof. The compound or a salt thereof stimulates the citric acid cycle activity and/or...
|
|
WO/2014/206922A1 |
This invention relates to novel sulfoximine substituted quinazoline derivatives of formula (I) wherein Ar, R1 and R2 are as defined in the description and claims, and their use as MNK1 (MNK1 a or MNK1 b) and/or MNK2 (MNK2a or MNK2b) kina...
|
|
WO/2014/205592A1 |
Compounds of formula (I) that are useful as hepatitis C virus (HCV) NS5B polymerase inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5B polymerase activity, for treating or preventing HCV in...
|
|
WO/2014/174532A2 |
The present invention provides an improved process for the preparation of emtricitabine with high yield and purity.
|
|
WO/2014/153214A1 |
Described herein are compounds of Formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds described herein are useful for inhibiting arginine methyltransferase activity. Methods of using...
|
|
WO/2014/135495A1 |
The present invention discloses compounds of Formula I: wherein the variables in Formula I are defined as described herein. Also disclosed are pharmaceutical compositions containing such compounds and methods for using the compounds of F...
|
|
WO/2014/130565A1 |
The present invention relates to substituted diaryl azetidine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.
|
|
WO/2014/079356A1 |
Emtricitabine sylicylate crystalline, preparing methods and uses thereof are disclosed. The chemical structure of emtricitabine sylicylate is shown in formula 2, wherein, when n=0, formula 2 represents anhydrous emtricitabine sylicylate,...
|
|
WO/2014/061991A1 |
The present invention relates to a novel organic electroluminescent compound and an organic electroluminescent device containing the same. By using the organic electroluminescent compound according to the present invention, an organic el...
|
|
WO/2014/044738A1 |
The present invention relates to benzoimidazole-carboxylic acid amide compounds of the formula I, in which R', R", R"', R1, R2, R3, R4, R5, R6 and Z are defined as indicated below. The compounds of the formula I are APJ receptor modulato...
|
|
WO/2014/037340A1 |
The invention relates to the use of substituted 2-amidobenzimidazoles, 2-amidobenzoxazoles and 2-amidobenzothiazoles of general formula (I) or the salts thereof, the groups in general formula (I) corresponding to the definitions cited in...
|
|
WO/2014/034533A1 |
There is provided an actinic ray-sensitive or radiation-sensitive resin composition containing a compound represented by Formula (1): wherein R1 represents a polycyclic aromatic group or a polycyclic heterocyclic aromatic group, R2 repre...
|
|
WO/2014/024880A1 |
This organic electroluminescent element is characterized by: having a positive electrode, a negative electrode provided facing the positive electrode, and an organic layer provided between the positive electrode and the negative electrod...
|
|
WO/2014/004064A1 |
Disclosed are compounds of Formula 1, including all stereoisomers, N-oxides, and salts thereof, wherein L is C(R12a)R12b-C(R13a)R13b-, wherein the carbon atom bonded to R12a and R12b is also bonded to the carboxamide nitrogen atom in For...
|
|
WO/2013/178083A1 |
A nucleotide analog preparation method, in particular to a lamivudine or emtricitabine preparation method, comprising: reducing in methanol a compound as represented by formula II in the presence of a reducing agent, thus yielding a reac...
|
|
WO/2013/168066A1 |
The invention provides an improved process for the manufacture of Lamivudine Form I by adding a solution of Lamivudine in a mixture of water C1-4 alcohol into C3-8 ketone.
|
|
WO/2013/156318A1 |
The present invention relates to substituted pyrazoles of formula (I), wherein the variables have the meaning as defined in the description, combinations of these compounds and other pesticides, methods and use of these compounds and com...
|
|
WO/2013/151297A1 |
The present invention relates to novel organic electroluminescent compounds and an organic electroluminescent device containing the same. The organic electroluminescent compounds according to the present invention can be used as a phosph...
|
|
WO/2013/124238A1 |
The invention relates to sulfinyl aminobenzamides of general formula (I) acting as herbicides. In formula (I), R, R', R", X, W and Z represent groups such as hydrogen, organic groups such as alkyl, and other groups such as halogen. Q rep...
|
|
WO/2013/117649A1 |
Novel imidazolopyridines according to Formula I, able to inhibit JAK are disclosed, wherein R1 and Cy are as disclosed herein. These compounds may be prepared as a pharmaceutical composition, and may be used for the prevention and treatm...
|
|
WO/2013/117645A1 |
Wherein R1, L1, R3, R4, Cy, L2 and R5 are as defined herein. Novel imidazolopyridines according to Formula I, able to inhibit JAK are disclosed, these compounds may be prepared as a pharmaceutical composition, and may be used for the pre...
|
|
WO/2013/064461A2 |
The present invention relates to the use of predominantly known pyridyl carboxamide derivatives as nematicides, compositions containing such compounds and methods for the control of nematodes.
|
|
WO/2013/032591A1 |
Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, incl...
|
|
WO/2013/027168A1 |
Disclosed are compounds of Formula (I): (I) which are useful as bromodomain inhibitors. Pharmaceutical compositions containing compounds of Formula (I) and the use of compounds of Formula (I) to treat diseases or disorders that are bromo...
|
|
WO/2013/021290A1 |
The present invention relates to a stereoselective glycosylation for the preparation of 1,3-oxathiolane nucleoside in high yield and high optical purity. The invention specifically relates to a process of the preparation of Lamivudine an...
|
|
WO/2013/016193A2 |
The present invention provides compounds of Formulae (A), (B), (C), and (D), pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof...
|
|
WO/2012/155199A1 |
The present invention relates to compounds useful in the modulation of potassium channel activity in cells, in particular the activity of Kv1.3 channels found in T cells. The invention also relates to the use of these compounds in the tr...
|
|
WO/2012/143317A1 |
The present invention relates to novel pyrazoles of formula (I) wherein the variables are as defined in the description, a method for controlling invertebrate pests, a method for protecting plant propagation material and/or the plants wh...
|
|
WO/2012/140001A1 |
The present invention relates to the use of dicarboximide derivatives of formula (I) as defined in the description, and the N-oxides, and salts thereof for combating harmful fungi and seed coated with at least one such compound. The inve...
|
|
WO/2012/131541A1 |
The present invention provides a process for the isolation of 4-amino-5-fluoro-1- [(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-2(1H)-pyrimi
dinone (emtricitabine) of formula I from the reaction mixture obtained by reacting (1R,2S,5R)-...
|
|
WO/2012/123409A1 |
N-(1,2,5-oxadiazol-3-yl)-, N-(tetrazol-5-yl)- and N-(triazol-5-yl)bicycloarylcarboxamides. N-(1,2,5-oxadiazol-3-yl)-, N-(tetrazol-5-yl)- and N-(triazol-5-yl)bicycloarylcarboxamides of the general formula (I) are described as herbicides. ...
|
|
WO/2012/122171A1 |
Disclosed are compounds of Formula 1, including all stereoisomers, N oxides, and salts thereof, A is a radical selected from the group consisting of, and B1, B2, B3, T, R1, R2 R3, R4, R5, R6, R7, R8, R9, R10, R11, R12 and R13 are as defi...
|
|
WO/2012/012941A1 |
New Bcl-2 family protein inhibitors, their cyclodextrin inclusion compounds, cyclodextrin complexes, and the uses in the manufacture of BH3 analogs, Bcl-2 family protein inhibitors thereof are disclosed. The acenaphthoheterocycle compoun...
|
|
WO/2012/003642A1 |
Fused tricyclic compounds of formula (I) and pharmaceutically acceptable salts thereof are disclosed, wherein X1, X2, X3, X4, Y1, Y2, M1, M2, Ra, Rb, R1, R2 and R6 are as defined in the description. Compositions comprising at least one f...
|
|
WO/2012/001107A1 |
The invention relates to new piperidine derivatives of the formula (I) to their use as medicaments, to methods for their therapeutic use and to pharmaceutical compositions containing them.
|
|
WO/2011/141805A2 |
The present invention relates to an improved process for the Manufacture of Lamivudine. A process for the preparation of essentially enantiomerically pure (-)-[2R, 5S]-4-amino-1-[2- (hydroxymethyl)-1,3-oxathiolan-5-y1]-2(1H)-pyrimidin-2-...
|
|
WO/2011/120927A1 |
The invention refers to a process for obtaining or isolating emtricitabine which comprises the azeotropic distillation of methanol-B(OMe)3. The invention is also directed to emtricitabine having a content of boron species of not more tha...
|
|
WO/2011/107494A1 |
The invention relates to aromatic glycoside derivatives of the formula (I), in which the groups have the given meanings, to the physiologically acceptable salts thereof, and to methods for the production thereof. The compounds are suitab...
|
|
WO/2011/107920A1 |
The present invention provides an improved process for stereoselective preparation of 5-fluoro-l-(2R,5S)-[2-(hydroxymethyl)-l,3-oxathiolan-5-yl]cy
tosine and pharmaceutically acceptable salts thereof.
|
|
WO/2011/103762A1 |
Lamivudine oxalate, preparation method and crystalline forms thereof are disclosed. A preparation method for lamivudine is also disclosed.
|
|
WO/2011/095987A1 |
The present invention relates to an improved process for the preparation of cis-nucleoside derivative of formula-1 involving chlorination of the compound of formula-2 followed by reaction with compound of formula-3 in presence of a base ...
|
|
WO/2011/080256A1 |
The present invention relates to hydroximoyl-tetrazole derivatives of Formula (I), their process of preparation, their use as fungicide active agents, particularly in the form of fungicide compositions and methods for the control of phyt...
|
|
WO/2008/079988A9 |
The invention provides novel compounds that are inhibitors of PDK1. Also provided are pharmaceutical compositions including the compounds, and methods of treating proliferative diseases, such as cancers, with the compounds or compositions.
|
|
WO/2011/045815A2 |
The present invention relates to novel salts of Lamivudine and method for the preparation thereof. The present invention also relates to processes for the preparation of crystalline Lamivudine Form-I and Form-II from novel salts of Lamiv...
|
